Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
Lung Cancer
Predicting Lung Cancer: Risk-Based LDCT Screening vs Age and Pack-Years
Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?
Endobronchial Ultrasound-Guided TBNA Outcomes in Patients Aged 65 and Above
How do outcomes of endobronchial ultrasound-guided transbronchial fine needle aspiration differ in patients aged 65 or older vs those younger than 65?
Do Veterans Receive Lung Cancer Screening at Recommended Intervals?
Researchers explored whether a cohort of veterans had received the 3 consecutive annual lung cancer screenings recommended to reduce lung cancer mortality.
Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint
The phase 3 study compared tiragolumab plus atezolizumab with placebo plus atezolizumab in adults with PD-L1 high locally advanced, unresectable or metastatic NSCLC.
Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC
The sBLA is supported by data from the phase 2 DESTINY-Lung01 trial, along with a phase 1 trial published in Cancer Discovery.
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
Trial Evaluating Tiragolumab Combo for Extensive-Stage SCLC Misses Endpoint
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response to cancer.
FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC
Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.
Opdivo Plus Chemotherapy Approved for Neoadjuvant Treatment of Resectable NSCLC
The approval was based on data from the CHECKMATE-816 trial.
